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Methods
Analysis of Clinical Outcomes and
Treatment Response
• 65 ER+/HER2- patients from MD
Anderson’s CDK4/6i cohort – a
collection of metastatic breast cancer
patients that received CDK4/6i therapy
and then progressed – were selected
for analysis
• All 65 patients chosen received
palbociclib as their CDK4/6i
• All have had biopsies performed
on treatment-naïve metastases;
biopsies stored as FFPE slides
• The 65 patients were divided into 6
categories depending on PFS and the
type of treatment received
• Intermediate progressors could
act as a unique group, or be split
between early and late
progressors
• The categories were used to create




Metastatic ER+/HER2- breast cancer patients receiving therapy with
CDK4/6 inhibitors present distinct molecular profiles that contribute
to either acquired or intrinsic resistance to therapy. We hypothesize
that second line treatment of palbociclib in combination with
endocrine therapy such as fulvestrant will lead to worse outcomes
compared to first line treatment of palcociclib and aromatase
inhibitors such as letrozole due to different mechanisms of action
that will influence the patient’s molecular profile.
Results - Clinical 
Discussion
• There is a significant difference in OS based on acquired 
vs. intrinsic resistance
• Suggests the existence of unique biomarkers that are 
characteristic of an intrinsic resistance phenotype
• While letrozole and fulvestrant might contribute to different 
PFS rates, they do not impact OS
• Fulvestrant might promote mutations that contribute to 
earlier intrinsic resistance than letrozole
Background
• While breast cancer in general has good 5-year survival rates, metastatic
breast cancer specifically has a poor 5-year survival rate of ~25% [1, 2]
• Probability of metastatic recurrence rises every year after initial treatment
ends; 20-30% of all early breast cancers will eventually experience a
metastatic recurrence [2, 3]
• Primary treatment of ER+/HER2- metastatic breast cancer uses hormone
therapy, but developing resistance is common and can be quick [4]
• Palbociclib, a CDK4/6 inhibitor (CDK4/6i) that halts cell cycle progression,
significantly improves PFS in conjunction with standard hormone therapies
used to treat ER+/HER2- metastases, but resistance is still inevitable [4, 5]
• Lack of verified biomarkers for palbociclib resistance [5]
65 patients
















Figure 1. Division of 65 cohort
patients into the 6 categories used for
comparison. Note that early
progressors can also be referred to
as “intrinsic resistance” and late
progressors as “acquired resistance”
Gene Analysis of Patient Cohort and Determination of
Biomarkers
• RNA was extracted from patient FFPE slides and underwent
Illumina RNA Exome sequencing
• Sequencing method enriches known exon sequences;
designed to work on degraded and/or low quality
samples
• Sequencing data entered standard RNA processing and DEG
analysis pipeline; note that while the overall steps are
standard, the details, programs, parameters are not and
depend on the specific research project’s data and goals
• Due to low quality of samples, special emphasis placed on





Figure 3. KM plots generated from clinical OS and PFS
data using the N=65 palbociclib cohort. Significant p-
values are boxed in red, non-significant are boxed in
blue. All depicted plots have intermediate progressors
split into early and late progressor groups rather than
act as an independent third group.
A.) PFS for early progressors vs late progressors
shows results which match expectations given that
early and late progressors are defined by PFS.
B.) OS for early progressors vs. late progressors
indicates that this significant difference extends to
OS, with intrinsic resistance associated with
significantly worse outcomes in patients.
C.) PFS for early first line treatment vs early
second line treatment was the only significant KM
plot among all first vs second line comparisons,
and indicates that second line treatment
(fulvestrant) may cause specific mutations that
contribute to earlier intrinsic resistance than
letrozole.
D.) OS for early first line treatment vs early second
line treatment indicates that this difference in
treatment is only applicable to PFS, and the two
different treatment options will not affect overall
survival.
Figure 2. Flowchart of gene analysis procedure. Starts from
Illumina sequencing and ends with testing of preliminary gene
signatures. Indicates program(s) used when applicable.
Comparison among biomarkers and correlation 
to clinical outcomes
Generation of preliminary gene signatures
Gather biological information for genes of interest
DEG and GSEA analysis
Normalization of reads
tximport and DESeq2
Quantification of aligned reads
RSEM




Filtering and trimming of raw sequences
cutadapt






























• Complete normalization of quantified RNA-seq data using 
DESeq2
• Perform DEG and GSEA analysis on normalized 
sequencing data
• Look for patterns found in palbociclib cohort KM plots in 
the larger CDK4/6i cohort
Results - Gene Analysis
• All steps up to normalization of reads using DESeq2 have 
been completed
• Overall data quality appears good:
• fastQC data reveals a majority of samples have good 
quality sequences with minimal overall contamination
• Alignment rates match expectations based on 
previous literature using STAR alignment in 
conjunction with Illumina RNA Exome sequencing
